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A B S T R A C T
Glycosaminoglycans (GAGs), dermatan sulfate (DS), heparan sulfate (HS), and keratan sulfate (KS), are the
primary biomarkers in patients with mucopolysaccharidoses (MPS); however, little is known about other bio-
markers. To explore potential biomarkers and their correlation with GAGs, blood samples were collected from 46
MPS II patients, 34 MPS IVA patients, and 5 MPS IVB patients. We evaluated the levels of 8 pro-inﬂammatory
factors (EGF, IL-1β, IL-6, MIP-1α, TNF-α, MMP-1, MMP-2, and MMP-9), collagen type II, and DS, HS (HS0S,
HSNS), and KS (mono-sulfated, di-sulfated) in blood.
Eight biomarkers measured were signiﬁcantly elevated in untreated MPS II patients, compared with those in
normal controls: EGF, IL-1β, IL-6, HS0S, HSNS, DS, mono-sulfated KS, and di-sulfated KS. The same eight bio-
markers remained elevated in ERT-treated patients. However, only three biomarkers remained elevated in post-
HSCT MPS II patients: EGF, mono-sulfated KS, and di-sulfated KS. Post-HSCT patients with MPS II showed that
IL-1β and IL-6 were normalized as HS and DS levels decreased. Eight biomarkers were signiﬁcantly elevated in
untreated MPS IVA patients: EGF, IL-1β, IL-6, MIP-1α, MMP-9, HSNS, mono-sulfated KS, and di-sulfated KS, and
four biomarkers were elevated in MPS IVA patients under ERT: IL-6, TNF-α, mono-sulfated KS, and di-sulfated
KS. There was no reduction of KS in the ERT-treated MPS IVA patient, compared with untreated patients. Two
biomarkers were signiﬁcantly elevated in untreated MPS IVB patients: IL-6 and TNF-α.
Reversely, collagen type II level was signiﬁcantly decreased in untreated and ERT-treated MPS II patients and
untreated MPS IVA patients.
In conclusion, selected pro-inﬂammatory factors can be potential biomarkers in patients with MPS II and IV as
well as GAGs levels.
1. Introduction
Mucopolysaccharidoses (MPS) are a group of lysosomal storage
diseases, characterized by the accumulation of glycosaminoglycans
(GAGs) and resulting in progressive cellular damage and successive
multiple organ failures. There are ﬁve types of accumulated GAGs in
tissue, dermatan sulfate (DS), heparan sulfate (HS), keratan sulfate
(KS), chondroitin sulfate, and hyaluronan, depending on the type of
MPS.
MPS II, also known as Hunter syndrome, is the only MPS with X-
linked inheritance, caused by a deﬁciency of iduronate-2-sulfatase (I2S)
enzyme and progressive accumulation of DS and HS. MPS II patients
present multiple progressive symptoms: coarse face, central nervous
system (CNS) involvement, airway obstruction, sleep apnea, cardio-
myopathy, hearing loss, stiﬀ joints, umbilical and inguinal hernias,
hepatosplenomegaly, and skeletal deformities [1].
MPS IV, also known as Morquio syndrome, is divided into two
subtypes: MPS IVA and MPS IVB, caused by the deﬁciency of N-acet-
ylgalactosamine-6-sulfate sulfatase (GALNS) and β-galactosidase (β-
Gal), respectively. KS accumulates in MPS IVA and MPS IVB due to the
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lack of these enzymes. In MPS IVA patients, disrupted cartilage leads to
unique skeletal features: short stature, short neck, odontoid hypoplasia,
spinal cord compression, tracheal obstruction, pectus carinatum, ky-
phoscoliosis, platyspondyly, coxa valga, genu valgum, waddling gait,
and laxity of joints [2]. In general, MPS IVB patients exhibit phenotypes
milder than those found in MPS IVA. MPS IVB is characterized by
skeletal dysplasia, corneal clouding, cardiac insuﬃciency and increased
urinary excretion of KS. There is no CNS involvement in both MPS IVA
and MPS IVB [3].
Simonaro et al. showed that GAG storage in MPS leads to cytokine
elevation in aﬀected cells and animals [4]. When the inﬂammatory
cytokines stimulate MPS connective tissue cells, it causes enhanced
secretion of several matrix-degrading metalloproteinases (MMPs),
leading to degradation of extracellular matrix (ECM) components, as
well as increased apoptosis of connective tissue cells and cartilage de-
struction [4–6]. A further study found that GAGs bind TLR4 receptors
and activate the TLR4 pathway, leading to cytokines such as TNF-α and
IL-1β release. Inactivation of this pathway in MPS VII mice lacking
TLR4 corrected many clinical and pathological features of the disease,
and an anti-TNF-a drug in MPS VI rats reduced levels of inﬂammatory
cytokines and improved joint pathology [7]. In addition to anti-TNF-α
therapy, pentosan polysulfate (PPS) has been studied as well. PPS has a
potent anti-inﬂammatory eﬀect and is approved by the FDA as an oral
medication (Elmiron®). Previous studies demonstrated that PPS in MPS
VI rats reduced inﬂammation and GAG levels and improved mobility
and organ system pathologies [8,9]. A small clinical trial in 4 adult
patients with MPS I indicated that PPS was well tolerated and that PPS
decreased GAG excretion and improved joint mobility and pain [10].
Orii et al. also demonstrated that PPS improved the range of joint
motion of adult patients with MPS II [11]. Thus, these ﬁndings conﬁrm
the critical role of inﬂammation in MPS and a strong positive eﬀect of
anti-inﬂammatory therapies. Polgreen et al. indicated that TNF-α was
associated with pain and physical disability, despite treatment under
ERT and/or HSCT [12]. Jacques et al. showed the elevation of TNF-α
and IL-1β in plasma from MPS II patients under ERT, compared to
controls [13]. Donida et al. also indicated that pro-inﬂammatory and
pro-oxidant states occur in MPS IVA patients even under ERT [14].
These studies conﬁrmed the persistence of inﬂammation despite
therapies such as ERT.
Here we examine the levels of pro-inﬂammatory factors in patients
with MPS II and IV and evaluate the correlation between pro-in-
ﬂammatory factors and GAGs accumulation. Considering that pro-in-
ﬂammatory factors and GAGs play an important role in inﬂammation
and that few studies have focused on the correlation between pro-in-
ﬂammatory factors and GAGs, we suggest that this study may help
better understanding of pathology in MPS.
2. Materials and methods
2.1. Subjects
There are no exclusion criteria, and inclusion criteria are that the
patient is diagnosed as MPS II, IVA or IVB. We provide the table as
supplementary for demographics of 85 patients including 46 MPS II
patients, 34 MPS IVA patients, and 5 MPS IVB patients. Twenty-ﬁve out
of 26 MPS II patients from Japan are deﬁned as severe, but the phe-
notype in 20 MPS II patients is unknown from Brazil. Thirty-two out of
34 MPS IVA patients are deﬁned as severe while two patients are as
attenuated. Five MPS IVB are deﬁned as classic. In this study, we col-
lected blood samples from 46 MPS II patients with ages ranging be-
tween 2 and 25 years (mean ± SD; 10.0 ± 5.53), 34 MPS IVA patients
with ages ranging between 3 and 56 years (16.4 ± 12.6), 5 MPS IVB
patients with ages ranging between 12 and 18 years (15.8 ± 2.8), and
61 normal controls in total with ages ranging between 0 and 32 years
(6.58 ± 6.93) with informed consent. Six MPS IVA patients were under
ERT for 8.83 ± 3.31months. Sixteen MPS II patients are under ERT (at
least over one month). Five MPS II patients are under HSCT for
9.00 ± 4.27 years. This study was approved by IRB at Nemours/Alfred
I. duPont Hospital for Children.
Some of the pro-inﬂammatory factors have been analyzed with a
limited number of the sample because of shortness of samples, leading
to a limitation of interpretation in this study.
2.2. Immunoassays
EGF, TNF-α, IL-1β, IL-6, and MIP-1α were measured in plasma or
serum by Milliplex Human Cytokine / Chemokine Non-Magnetic 96-
well Plate, performed according to manufacturer's instruction (Cat #;
MPXHCYTO-60 K). MMP-1, MMP-2, and MMP-9 were measured in
plasma or serum by Milliplex map kit, according to the manufacturer's
instruction. The plasma dilution for MMPs (MMP-1, MMP-2, and MMP-
9) was established as 1:20.
Type IIA collagen N-Propeptide (PIIANP) was measured in serum by
enzyme-linked immunosorbent assay (ELISA) kit, according to the
manufacturer's instruction. The ELISA plate was read absorbance at
450 nm and 590 nm. The serum dilution for PIIANP was established as
1:10.
2.3. Glycosaminoglycan assay
We developed a highly accurate, sensitive, and cost-eﬀective liquid
chromatography-tandem mass spectrometry (LC-MS/MS) method to
measure the four disaccharides produced from GAGs; CS, DS, HS and KS
[15–17]. Brieﬂy, DS, HS, and KS in human serum and plasma were
digested to disaccharides by chondroitinase B, heparitinase, and kera-
tanase II, respectively. Analysis of disaccharides [DiHS0S (HS0S),
DiHSNS (HSNS), DiHS6S (DS), mono-sulfated KS, di-sulfated KS] was
performed by LC-MS/MS with multiple reactions monitoring in the
negative ion mode. Separation of LC was performed on a Hypercarb
(2.0 mm i.d.× 150mm, 5 μm) with a gradient elution of acetoni-
trile–0.01M ammonium bicarbonate (pH 10). The mobile phase ﬂow
rate was 0.2ml/min. The 6460 triple quad mass spectrometer with a
1290 Inﬁnity LC system (Agilent Technologies, Palo Alto, CA) was used
to determine each GAG in the serum or plasma of MPS patients and
controls.
2.4. Statistical analysis
Multiple comparison tests were performed by one-way ANOVA with
Tukey's post-hoc test using GraphPad Prism 5. The statistical sig-
niﬁcance of diﬀerence was considered as p < .05. Pearson's correlation
coeﬃcient test was used to ﬁnd the correlation between each pro-in-
ﬂammatory factors and GAGs, between age and BMI, and between
biomarkers and age.
3. Results
3.1. Pro-inﬂammatory factors and collagen type II
Pro-inﬂammatory factors (EGF, TNF-α, IL-1β, IL-6, MIP-1α, MMP-1,
MMP-2, and MMP-9), as well as type IIA collagen (PIIANP), were as-
sayed.
Three pro-inﬂammatory biomarkers were signiﬁcantly elevated in
untreated and ERT-treated MPS II patients, compared to those in
normal controls: EGF, IL-1β, and IL-6. The EGF level was also elevated
in MPS II patients treated with HSCT, but the level was lowered,
compared with untreated MPS II patients. The only EGF level was
elevated in MPS II patients treated with HSCT, but the level was low-
ered, compared with untreated and ERT-treated MPS II patients. The
MMP-1 level was decreased in untreated patients, compared to that in
normal controls.
Five pro-inﬂammatory biomarkers measured were signiﬁcantly
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elevated in untreated MPS IVA patients, compared to normal controls:
EGF, IL-1β, IL-6, MIP-1α, and MMP-9. Levels of IL-6 and TNF-α were
signiﬁcantly elevated in MPS IVA patients under ERT and untreated
MPS IVB patients, compared to those in normal controls (two bio-
markers, IL-1β and MIP-1α, could not be evaluated in this study be-
cause of the shortage of samples). Two pro-inﬂammatory biomarkers
(IL-6, TNF-α) were signiﬁcantly elevated in MPS IVA patients under
ERT compared with untreated MPS IVA patients while MMP-1 was
elevated in untreated MPS IVA.
PIIANP level was signiﬁcantly decreased in untreated and under
ERT MPS II patients and untreated MPS IVA patients, compared to that
in normal controls (Fig. 1). ERT-treated and post-HSCT MPS II patients
and ERT-treated MPS IVA patients tended to a lower PIIANP level.
3.2. GAG levels
Levels of DiHS0S, DiHSNS, and DS were signiﬁcantly increased in
patients with MPS II (untreated and under ERT), compared to the levels
in normal controls. Levels of DiHS0S, DiHSNS, and DS were sig-
niﬁcantly lower in MPS II patients treated with HSCT than those in
untreated MPS II patients. MPS II patients with HSCT had lower levels
of DiHS0S, DiHSNS, and DS than patients with ERT.
Levels of mono-sulfated KS and di- sulfated KS were signiﬁcantly
elevated in patients with MPS II (untreated, ERT-treated, and post-
HSCT) and MPS IVA (untreated and ERT-treated), compared to those in
normal controls (Fig. 2). There was no tendency of decrease of KS in
both ERT-treated and post-HSCT patients with MPS II as well as ERT-
treated patients with MPS IVA, compared with KS in untreated MPS II
or MPS IVA patients.
Fig. 1. Blood levels of pro-inﬂammatory factors and collagen type II in patients with MPS and normal control. (a) EGF, (c) IL-1β, (e) IL-6, (g) TNF-α, (i) MIP-1α, (k)
MMP-1, (m) MMP-2, (o) MMP-9 and (q) Collagen type II levels in patients with MPS II. (b) EGF, (d) IL-1β, (f) IL-6, (h) TNF-α, (j) MIP-1α, (l) MMP-1, (n) MMP-2, (p)
MMP-9 and (r) Collagen type II levels in patients with MPS IV. *p < .05 vs normal control group. #p < .05 vs MPS IVA untreated patients.
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3.3. Correlation between biomarkers
We have investigated the correlation between pro-inﬂammatory
factors or PIIANP and speciﬁc GAGs. In all patients with MPS II, IVA,
and IVB, EGF moderately correlated with DiHS0S, DiHSNS, and DS
(Pearson's r; 0.5954, 0.6329, and 0.4037, respectively) while there was
no correlation with KS.
PIIANP had a weak to moderate negative correlation with DiHS0S,
DiHSNS, and DS (Pearson's r; −0.3829, −0.4011, and− 0.3273, re-
spectively) while there was no correlation with KS.
3.4. Correlation between biomarkers and age
In all MPS patients, mono-sulfated KS correlated negatively with age
(Pearson's r; −0.5255).
In normal controls, EGF, DiHS0S, and mono-sulfated KS correlated
negatively with age (Pearson's r; −0.4372, −0.535, −0.5405 respec-
tively). In untreated MPS II patients, MMP-2 and DiHS6S correlated
negatively with age, and Col II correlated positively with age (Pearson's
r; −0.4442, −0.4726, 0.5131 respectively). In MPS II patients under
ERT, IL-6 and DiHS0S correlated negatively with age (Pearson's r;
−0.6723, −0.5607 respectively). In untreated MPS IVA patients,
mono-sulfated KS, and di-sulfated KS correlated negatively with age
(Pearson's r; −0.6714, −0.4272 respectively). In MPS II patients post-
Fig. 1. (continued)
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HSCT, MPS IVB patients and MPS IVA patients under ERT, no bio-
markers correlated with age.
3.5. Correlation between biomarkers and BMI
In MPS II patients, a positive relationship was seen between BMI
and DiHS0S, DiHSNS, DS and Di-sulfated KS (Pearson's r; 0.723, 0.703,
0.732 and 0.642, respectively) while there was no correlation between
BMI and biomarkers in MPS IVA patients.
4. Discussion
In this study, we have demonstrated that pro-inﬂammatory factors
are potential biomarkers in patients with MPS II and IVA and that there
is a correlation between speciﬁc pro-inﬂammatory factors and GAGs.
HS and DS levels in blood were signiﬁcantly elevated in both un-
treated and ERT-treated MPS II patients, compared to those in normal
controls while HS and DS levels were signiﬁcantly reduced in post-
HSCT MPS II patients, compared with untreated patients (Fig. 2a). This
ﬁnding indicates that HSCT could provide more therapeutic eﬃcacy
than ERT, compatible with the previous data [18,19]. However, in post-
HSCT MPS II patients, HS0S and HSNS levels were still elevated,
compared to those in healthy controls while DS level was normalized.
HS is involved in multiple biological functions including modulating
the activity of growth factors [20]. MPS I, II, III, and VII patients cannot
properly degrade HS and its accumulation in the brain causes neuro-
logical symptoms. Tomatsu et al. indicated that blood HS levels in MPS
I, II, III, VI, and VII are elevated with a sandwich ELIZA method [21]
and that patients with a severe form had a higher elevation of HS in
blood [22]. Patients with untreated MPS II had higher levels of DS and
HS in blood while untreated MPS III had higher levels of HS in blood
than age-matched controls [18]. The levels of DS and HS were higher in
all newborn dried blood spots of MPS I and II patients, compared to
control newborns [15,23,24]. Thus, our results were matched with
previous studies, proving that HS is a useful biomarker in MPS II pa-
tients and that HS can be valuable for monitoring therapeutic eﬃcacy.
Our results showed that mono-sulfated KS and di-sulfated KS were
signiﬁcantly elevated in patients with MPS II (untreated, under ERT,
and post-HSCT) and MPS IVA (untreated and under ERT), compared
with those in normal controls, suggesting that ERT and/or HSCT did not
reduce KS levels in the blood. There was no improvement in the bone
lesion in MPS IVA patients with ERT in this study, indicating that the
measurement of blood KS is essential as a biomarker of the bone lesion
as previously suggested [18]. Bone lesions can be evaluated by growth
Fig. 1. (continued)
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(height) [25–30], skeletal survey with X-rays, CT and MRI
[2,27,31–33], BMD [34], surgical history [35,36], and pathological
ﬁndings from surgical remnants [37,38]. In MPS I, IVA, and VII mice,
the severity of skeletal disease displayed by micro-CT, radiographs, and
histopathology correlated with the level of KS elevation [39]. KS level
was normalized after neonatal bone marrow transplantation in MPS I
mice [40]. Patients with MPS II had a secondary elevation of KS in spite
of the normal levels of enzymes required to digest KS [20].
MPS IVA and IVB patients cannot properly degrade KS due to a
deﬁciency of GALNS (MPS IVA) and β-galactosidase (MPS IVB). The
accumulation of KS disrupts cartilage, resulting in the release of more
KS into circulation, which is a critical biomarker for MPS IVA. Blood KS
levels in MPS IVA patients were signiﬁcantly increased when compared
to those in age-matched controls [41]. KS level in MPS IVA patients
varied with age and clinical severity in patients [42–45,56]. Blood KS
levels in patients with severe MPS IVA were higher than in the atte-
nuated form [41]. Plasma KS levels varied with age in both control and
MPS I, II, III, VI, and VII patients [46,47,48]. Both blood and urine KS
are only valuable as biomarkers in younger patients before the growth
plate is closed or destroyed since the synthesis of KS decreases clearly
after teenage and levels of KS in MPS IVA patients are naturally nor-
malized or subnormal by the age of 20 years [49]. Shimada et al. in-
dicated that blood mono- and di-sulfated KS levels in patients with MPS
IVA are signiﬁcantly higher than those in age-matched control subjects,
that the level of blood di-sulfated KS distinguishes control subjects and
patients with MPS IVA more clearly than that of mono-sulfated KS, and
that blood mono- and di-sulfated KS levels are signiﬁcantly higher in
patients with MPS II than those in age-matched control subjects [50].
Our results were matched with those in these studies, conﬁrming that
mono-sulfated KS and di-sulfated KS are a clear biomarker to reﬂect
bone lesions and therapeutic eﬃcacy in both MPS II and MPS IVA.
Our ﬁndings showed that EGF levels are higher in patients with MPS
II (untreated, under ERT, and post-HSCT) and untreated MPSIVA,
compared with those in normal controls and that these patients have
higher GAGs levels as well. Pisano et al. indicated that stimulation of
ornithine decarboxylase by EGF and prostaglandins leads to an increase
in the synthesis of GAGs in embryonic palate mesenchymal cells [51].
Banecka et al. also showed that an excessive EGF stimulates GAG
synthesis in MPS ﬁbroblasts, as it shows that under such conditions,
accumulation of GAGs is more prominent in untreated patients with
various types of MPS [52]. Genistein is a speciﬁc inhibitor of the tyr-
osine-speciﬁc protein kinase activity of the EGF receptor [52], which
reduce GAG synthesis [9]. Taken together, the current results conﬁrmed
those in previous studies, suggesting that EGF increases GAG synthesis
and should be an excellent biomarker to reﬂect GAG level in patients
with MPS.
In this study, we also found in pro-inﬂammatory factors that 1) the
TNF-α level was signiﬁcantly higher in patients with ERT-treated MPS
IVA and untreated MPS IVB, compared with those in normal controls,
that 2) IL-1β levels were signiﬁcantly higher in patients with MPS II
(untreated and under ERT) and untreated MPS IVA, compared with
those in normal controls, that 3) IL-6 levels were signiﬁcantly higher in
patients with MPS II (untreated and under ERT), MPS IVA (untreated
and under ERT), and MPS IVB, compared with those in normal controls,
and that 4) macrophage inﬂammatory protein 1 alpha (MIP-1α) level
was signiﬁcantly higher in patients with untreated MPS IVA, compared
with that in normal controls.
In 2005, Simonaro et al. showed that GAG storage in MPS leads to
cytokine elevation in MPS cells and animals. Cytokines are produced by
MPS chondrocytes, synoviocytes, and macrophages, and signiﬁcantly
up-regulate MMP gene expression [4]. A further study found that GAGs
bind TLR4 receptors and activate the TLR4 pathway, leading to TNF-α
and another cytokine release [7]. IL-1 aﬀects almost every cell type,
often in conjunction with TNF [53]. IL-1 and TNF are pro-inﬂammatory
cytokines which induce autophagy to improve infection controls [5].
Polgreen et al. indicated that the TNF-α level was signiﬁcantly higher in
children and adolescents with MPS, compared to the levels in healthy
children. TNF-α was associated with pain and physical disability, de-
spite treatment with ERT and/or HSCT [12]. Jacques et al. also mea-
sured pro-inﬂammatory cytokines and showed the elevation of TNF-α
and IL-1β in plasma from MPS II patients with ERT, compared to con-
trols [13]. Donida et al. also indicated that the plasma levels of IL-6
Fig. 2. Blood GAGs levels in patients with MPS and normal control. (a) HS0S, HSNS, and DS levels in patients with MPS II, (b) HS0S, HSNS, and DS levels in patients
with MPS IV, (c) KS levels in patients with MPS II, (d) KS levels in patients with MPS IV. *p < .05 vs normal control group. #p < .05 vs MPS II untreated patients.
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were higher in MPS IVA patients under ERT, compared with controls
[14]. MIP-1α is an inﬂammatory chemokine playing an important role
in macrophage recruitment, inducing monocytes to inﬁltrate the CNS
and expanding the activated macrophage-microglial subpopulation.
MIP-1α level was signiﬁcantly higher in MPS IIIB mouse serum, com-
pared to that in normal mice [54]. PPS reduced serum MIP-1α levels in
MPS VI rats [8]. MIP-1α levels in MPS IVA patients were signiﬁcantly
higher, compared to healthy controls [55]. Our ﬁndings were matched
with these previous ﬁndings, proving that inﬂammation with an in-
crease of TNF-α, IL-1β, IL-6 and/or MIP-1α indeed occurs in patients
with MPS II and/or IVA.
This study has also demonstrated that MMP-9 levels were sig-
niﬁcantly higher in patients with untreated MPS IVA, compared with
those in normal controls, and that MMP-1 levels were signiﬁcantly
higher in patients with untreated MPS IVA, compared with those in
MPS IVA patients under ERT.
Simonaro et al. showed that when the inﬂammatory cytokines sti-
mulate MPS connective tissue cells, it causes enhanced secretion of
several matrix-degrading metalloproteinases (MMPs) [4]. MMPs are
proteinases that lead to degradation of extracellular matrix compo-
nents, as well as increased apoptosis of connective tissue cells and
cartilage destruction [5,6]. MMPs are involved in both normal and
pathological processes. MMP-1 cleaves interstitial collagens I, II, and
III, and digest a number of other ECM and non-ECM molecules [6].
Enhanced expression of MMP-2 and MMP-9 was observed in the MPS
animals, associated with abnormal expression of TIMP-1. Expression of
MMPs was signiﬁcantly enhanced in articular chondrocytes [4]. MMPs
are involved in numerous neuro-inﬂammatory diseases, and over-
production of MMPs is coupled with disruption of the blood-brain
barrier [56]. MMP-2 and MMP-9 are a suitable biomarker demon-
strating CNS involvement. Batzios et al. have indicated that MMP-2
expression was signiﬁcantly increased in serum, whereas a signiﬁcant
decrease in serum MMP-9 was observed in MPS III patients. In MPS VI
patients, the activity and protein levels of MMP-9 are decreased by ERT
up to 4months after starting of the treatment. In a MPS II patient, there
was a 2.6-fold increase of MMP-2 level in serum and a 0.25-fold de-
crease in MMP-9 level [57]. In MPS IVA patients, the MMP-2 level was
signiﬁcantly higher when compared to unaﬀected controls [55].
Thus, our ﬁndings were not compatible with the previous ﬁndings
in that MMP-2 levels were signiﬁcantly higher in untreated MPS IVA,
and it remains unclear that there was no increase of MMPs in untreated
MPS II patients.
In addition, we found that collagen type II was signiﬁcantly de-
creased in patients with MPS II (untreated and under ERT) and un-
treated MPS IVA, compared with those in normal controls. Collagen
Type II represents 90% to 95% of the collagen in the extracellular
matrix and forms ﬁbrils and ﬁbers intertwined with proteoglycan ag-
gregates [58]. Previous studies have proved that increased apoptosis of
MPS chondrocytes leads to a depletion of proteoglycans and total col-
lagen in the cartilage of MPS animals [59]. The study by de Francheschi
et al. showed low expression of collagen type II at the protein and
molecular levels in MPS IVA patients [60]. Our ﬁndings were compa-
tible with the previous results, showing that collagen type II can be as a
potential biomarker in patients with MPS II and IVA. It is critical to
know whether the increase of collagen type II in patients with post-
HSCT MPS II and ERT-treated MPS IVA correlates with speciﬁc clinical
improvement like skeletal dysplasia.
Overall, in both untreated and under ERT MPS II patients, the same
eight biomarkers were signiﬁcantly elevated, compared with those in
normal controls while in post-HSCT MPS II patients, four biomarkers
(IL-1β, IL-6, MMP-1, PIIANP) were normalized as HS and DS levels
decreased and three biomarkers (EGF, mono-sulfated KS, di-sulfated
KS) were still elevated, suggesting HSCT could provide more impact to
normalize biomarkers correlating with clinical improvements.
Meanwhile, three biomarkers (IL-6, TNF-α, MMP-1) were sig-
niﬁcantly diﬀerent between untreated MPS IVA patients and ERT-
treated MPS IVA patients; however, there was no reduction of KS in the
ERT-treated patient. This discrepancy between pro-inﬂammatory fac-
tors and blood KS level cannot explain by the currently limited data.
In this study, there was a correlation between several biomarkers
and age. In both patients and controls, mono-sulfated KS correlated
negatively with age while other biomarkers correlated with age in some
speciﬁc groups negatively or positively. It is required to consider the
age as potential confounders longitudinally when we compare the va-
lues of some speciﬁc biomarkers between controls and patients. BMI in
patients with MPS IVA correlated with age, which was compatible with
the previous results [35]. In MPS II patients, a positive relationship was
observed between BMI and GAGs. Therefore, it is also imperative to
assess BMI longitudinally as a confounder.
It is critical to investigate whether these biomarkers correlate with
therapeutic eﬃcacy and its clinical improvement to be used for the
potential clinical endpoint. The current data are based on a cross-sec-
tional study, and a limitation of our current study refers to a small
number of patients with MPS. Therefore, we need to compare the
longitudinal data with large numbers of patients with MPS between the
biomarkers and clinical severity or therapeutic eﬃcacy (growth, BMD,
pulmonary function, IQ/DQ, ADL, skeletal survey with X-rays, surgical
history, and pathological ﬁndings from surgical remnants) and corre-
lation between age and the biomarkers. The current data needs to be
conﬁrmed by age-dependent groups as well.
5. Conclusion
In conclusion, pro-inﬂammatory factors and collagen type II, as well
as GAGs, can be biomarkers in patients with MPS, depending on the
type of MPS and treatment method.
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